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Objective: The cell-mediated immune process by CD4+ and CD8+ lymphocyte subsets of T-cells has a major role
in the pathogenesis of Hashimoto’s thyroiditis (HT). However, the exact mechanisms of initiation and progression of
thyroid autoimmunity have not been completely clarified yet. Macrophage migration inhibitory factor (MIF) is
commonly recognized as playing vital roles in various autoimmune diseases. Ee aimed to investigate serum MIF
levels in subjects with HT and correlate them with the level of thyroid hormones and autoantibodies.
Materials and methods: This study included 93 patients with untreated Hashimoto’s thyroiditis and 53 healthy
controls. We measured serum levels of TSH, free T4 (FT4), free T3 (FT3), anti-thyroglobulin autoantibody (TGAb) and
anti-thyroid peroxidase autoantibody (TPOAb) in all patients and thyroid ultrasonography was performed. The
concentration of MIF was measured using enzyme-linked immunosorbent assay (ELISA) method.
Results: We enrolled 93 patients with HT (mean age; 31.3 ± 11.1 years), and 53 healthy control group (mean age;
29.3 ± 8.5 years) in the current study. The patient group consisted of 52 with euthyroid autoimmune thyroiditis, 31
with subclinical hypothyroidism and 10 with overt hypothyroidism. Serum levels of MIF were higher in patients
with overt hypothyroidism (6300.9 ± 2504.3 pg/ml) than the euthyroid patients (3955.2 ± 3013.6 pg/ml) (p = 0.036).
Conclusion: MIF increases in overt hypothyroidism due to the Hashimoto’s thyroiditis. Further investigations are
needed to explore the role of MIF in pathogenesis of Hashimoto’s thyroiditis.Introduction
Hashimoto’s thyroiditis (HT) is an autoimmune disease
that results in clinical hypothyroidism due to the thyroid
gland destruction and the usual course for HT is gradual
loss of thyroid function [1]. HT is characterized by the
presence of high serum levels of antibodies to thyro-
globulin and thyroid peroxidase and infiltration of the
thyroid gland by T-cells and B-cells histologically [1].
The cell-mediated immune process by CD4+ and CD8+
lymphocyte subsets of T-cells has a major role in the
pathogenesis of HT [2]. At the same time, cytokines pro-
duced by macrophages, T cells and thyroid follicular cells
have an important role in HT, especially in the initiation
and continuation of autoimmune disease [3]. While Th2* Correspondence: drthess@hotmail.com
1Department of Internal Medicine, Recep Tayyip Erdogan University, Faculty
of Medicine, Rize 53100, Turkey
Full list of author information is available at the end of the article
© 2014 Ayaz et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.type of CD4+ lymphocytes secrete interleukin-4 (IL-4),
IL-5 and IL-6 and promote production of antibodies, the
Th1 CD4+ lymphocytes secrete IL-2, interferon-gamma
(INF-ɤ) and tumor necrosis factor- alfa (TNF-α) [2-4]. In
spite of the intensive researches, the exact mechanisms of
initiation and progression of thyroid autoimmunity have
not been completely clarified yet.
Macrophage migration inhibitory factor (MIF) is a pleio-
tropic lymphocyte and macrophage cytokine involved in
the regulation of innate and adaptive immunity [5]. It pro-
motes the production of inflammatory Th1 cytokines,
including TNF-α, IFN-ɤ, IL-2, and IL-6 [6-8]. Moreover,
MIF inhibits p53 dependent apoptosis [9], and partici-
pates in T cell proliferation and activation [7,10].
There is increasing evidence for a role of MIF as a
proinflammatory cytokine in autoimmune diseases [11].
Serum levels of MIF have been shown to be elevated in
several autoimmune disorders including rheumatoidd. This is an Open Access article distributed under the terms of the Creative
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http://www.thyroidresearchjournal.com/content/7/1/11arthritis, Wegener’s granulomatosis and systemic lupus
erythematosus [12-14].
In the present study, we hypothesized that MIF may
have a potential role in the pathogenesis of HT. There-
fore, we investigated serum MIF levels in euthyroid and
hypothyroid subjects with HT and correlated them with
the level of thyroid hormones and autoantibodies.
Materials and methods
Study population
This study included 93 patients with untreated Hashi-
moto’s thyroiditis and 53 healthy controls. None of the
patients were receiving levothyroxine (LT4) or antithy-
roid drugs. Subjects with diabetes mellitus, renal or hep-
atic dysfunction, acute or chronic inflammatory disease,
cancer, infection diseases were excluded from the study.
All the participants gave a written consent.
Clinical and hormonal measurements
The patients having serum thyrotropin (TSH) levels over
4.9 μIU/ml and serum free T4 (fT4) levels below 0.75 ng/dl
were classified as overt hypothyroid group, the patients
having TSH levels over 4.9 μIU/ml and serum fT4 levels
0.75–1.48 ng/dl were classified as subclinical hypothyroid.
We measured serum levels of anti-thyroglobulin auto-
antibody (TGAb), anti-thyroid peroxidase autoantibody
(TPOAb) in all patients and thyroid ultrasonography
was performed in all patients. The patients with hashi-
moto’s thyroiditis (confirmation with antibody positivity
or sonographic appearance of thyroiditis) were included
in the study. TSH, FT3, FT4, TGAb andTPOAb levels
and ultrasound images were all normal in the control
group.
Venous blood samples were obtained from all subjects
following a 12-h overnight fasting. The levels of TSH
(N: 0.35-4.94 uIU/ml), free T3 (fT3) (N: 1.71- 3.71 pg/ml),
free T4 (fT4) (N: 0.7-1.48 ng/dl), TGAb (N: 0–4.11 uIU/ml)
and TPOAb (N: 0–5.61 uIU/ml) were measured using
chemiluminescent microparticle enzyme immunoassay
(CMIA) method with Abbott Architect i2000 (Abbott
Diagnostic, USA).
Measurement of MIF
The concentration of MIF was measured using enzyme-
linked immunosorbent assay (ELISA) method. We used
commercially available human MIF ELISA kit (abcam,
USA). The procedure for the ELISA method was accord-
ing to the instructions provided by the manufacturer.
Absorbance was measured at a wavelength of 450 ηm
using ELISA reader. The levels of MIF are presented as
pg/ml. The intra-assay and inter-assay coefficient of vari-
ation were <10% and <12%, respectively. The limit of de-
tection (LOD) for the MIF assay was 6 pg/ml.Statistical analysis
Data were analyzed using SPSS Software (Version 17,
SPSS, Inc., Chicago, IL, USA). Results were expressed as
mean ± standard deviation. Differences among the groups
not showing normal distribution were analyzed by the
Kruskal-Wallis test. Dual comparisons among groups with
significant values were evaluated with the Bonferroni ad-
justed Mann–Whitney U-test. The Chi-square test was
used to compare categorical variables. Spearman’s rank
correlation test was used for calculation of associations
between variables. A p value of less than 0.05 was consid-
ered to be statistically significant.Ethical approval
The procedures, used in the study, were approved by the
Ethics Committee of the Recep Tayyip Erdogan University,
Rize, Turkey ( 2014/46).Results
We enrolled 93 patients with HT (mean age; 31.3 ±
11.1 years), and 53 healthy control group (mean age;
29.3 ± 8.5 years) in the current study. The patient group
consisted of 52 euthyroid (group 1) and 41 hypothyroid
subjects. While 31 patients were diagnosed as subclinical
hypothyroid (group 2), 10 patients were diagnosed as overt
hypothyroid (group 3). The control subjects (group 4) were
not suffering from any health problems and were not
receiving any medications. There was no difference be-
tween the four groups in terms of age and sex. Most of
the subjects were female in the study population (89.2% in
HT group vs 83% in control group). The hormonal results
of the four groups are shown in Table 1.
Patients with overt hypothyroidism had lower fT4 levels
and higher TSH levels than euthyroid (p < 0.001, p < 0.001),
subclinical hypothyroid (p = 0.003, p < 0.001) and con-
trol group (p < 0.001, p < 0.001) respectively. There was
no significant difference between euthyroid and healthy
subjects by terms of TSH, however TSH levels were
higher in euthyroid patients (2.3 ± 1.1 μIU/ml) compared
to the controls (1.8 ± 0.9 μIU/ml) (p = 0.021). Patients with
subclinical and overt hypothyroidism had higher levels of
TPOAb than euthyroid patients (p = 0.002, p = 0.005) and
healthy subjects (p < 0.001, p < 0.001) respectively. TGAb
levels were significantly higher in euthyroid (p < 0.001),
subclinical (p < 0.001) and overt hypothyroid patients
(p < 0.001) compared to the control group. Serum levels of
TGAb were not different in euthyroid and hypothyroid
patients (p > 0.005).
Serum levels of MIF were significantly higher in patients
with overt hypothyroidism than the euthyroid patients
(p = 0.036). There were no associations of MIF levels
with age, TSH, fT3, fT4, TGAb and TPOAb levels in pa-
tients with HT (Table 2).
Table 1 The clinical, biochemical and hormonal results in patients with Hashimoto’s thyroiditis and healthy control
Variable Group 1 Group 2 Group 3 Group 4 p
(n = 52) (n = 31) (n = 10) (n = 53)
Age (years) 30.7 ± 9.9 30.1 ± 10 38 ± 17.6 29.3 ± 8.5 0.702*
Gender (F/M) 47/5 28/3 8/2 83% 0.572**
FT3 (pg/ml) 3.1 ± 0.2 3.1 ± 0.3 3.1 ± 0.4 3.2 ± 0.3 0.252*
FT4 (ng/dl) 1.0 ± 0.1 1.0 ± 0.1 0.8 ± 0.1 1.09 ± 0.12 <0.001*
TSH (μIU/ml) 2.3 ± 1.1 6.7 ± 1.6 23.6 ± 27.2 1.8 ± 0.9 <0.001*
TGAb (uIU/ml) 225.5 ± 281.4 239.5 ± 319.4 229.8 ± 248.1 1.7 ± 1.5 <0.001*
TPOAb (uIU/ml) 221.8 ± 361.4 386.7 ± 376.5 629.8 ± 464.1 0.7 ± 3 <0.001*
MIF(pg/ml) 3955.2 ± 3013.6 4599.8 ± 2717.9 6300.9 ± 2504.3 4971.2 ± 3054.4 0.044*
Values are expressed as means ± SD.
*Kruskal Wallis **Chi square test.
Group 1: euthyroid Hashimoto’s thyroiditis, group 2: subclinical hypothyroidism, group 3: overt hypothyroidism, group 4: control group. FT3; free T3, FT4; free T4, TSH;
thyroid stimulating hormone, TGAb; anti-thyroglobulin autoantibody, TPOAb; anti-thyroid peroxidase autoantibody, MIF; Macrophage migration inhibitory factor.
Ayaz et al. Thyroid Research 2014, 7:11 Page 3 of 5
http://www.thyroidresearchjournal.com/content/7/1/11Discussion
Our study shows that MIF may play a role in the patho-
genesis of HT, especially in the progression of disease.
Although the difference was not significant, we found
higher MIF levels in patients with overt hypothyroidism
compared to the euthyroid and subclininal hypothyroid
patients and healthy subjects (p = 0.098).
HT is an autoimmune disease manifesting as euthyr-
oidism or hypothyroidism, that is accompanied by
massive infiltration of lymphoid cells [15]. In the initial
stage, antigen-presenting cells (APC), mostly dendritic
cell and macrophage derived, infiltrate the thyroid gland
and present selfantigens and activate self-reactive naive
T cells and initiate an autoimmune response that can be
sustained by antigen presentation by the target cells [16].
Then, a central phase occurs in the draining lymph node
in which interactions between APC, autoreactive T cells
and B cells result in inducing production of thyroid
autoantibodies. In the next step, antigen-producing B
lymphocytes, cytotoxic T cells and macrophages infiltrate
and accumulate in the thyroid. This process is mediated
predominantly by Th1-type cytokines such as IL-1,
IL-6, and TNF- α [3]. In the final stage, the generatedTable 2 The correlation between serum levels of MIF,









FT3 free T3, FT4 free T4, TSH thyroid stimulating hormone, TGAb anti-thyroglobulin
autoantibody, TPOAb anti-thyroid peroxidase autoantibody.autoreactive T cells, B cells and antibodies cause massive
depletion of thyrocytes via antibody-dependent, cytokine
mediated and apoptotic mechanisms of cytotoxity that
leads to HT [16].
Th1/Th2 imbalance (predominance of Th1 cells) plays
the critical role in HT pathogenesis [15]. Multiple researchs
showed the important role of cytokines in directing auto-
immune and apoptotic pathogenic processes, of particular,
in central and late stages of the development of HT [16].
Nevertheless, the role of cytokines in systemic circulation
and their participation in the pathogenesis of HT still re-
main unclear. In a study, high levels of IL-6 and IL-15
were detected in the patients with HT [17]. In another
study, IL-12 and IL-18 levels were found to be higher in
patients with euthyroid HT than those in normal controls
[18]. Recently, Guo H et al. showed that the levels of
serum IL-22, IL-17A and IFN-γ in the newly diagnosed
HT patients were significantly higher than that in the
healthy subjects [19].
MIF is a pro-inflammatory mediator and an upstream
regulator of expression of many cytokines, including IL-
1b, IL-8, IFN-ɤ, TNF-α, and IL-6 in autoimmune diseases
[11]. One of the first clinical studies regarding MIF ex-
pression in autoimmunity was in patients with rheumatoid
arthritis [20]. Also, high serum levels of MIF were re-
ported in other autoimmune diseases such as SLE and
type 1 diabetes mellitus [14,21]. Taken together, these
findings suggest that MIF can contribute to the pathogen-
esis of HT by inducing production of proinflammatory cy-
tokines. In the current study, we observed that, serum
concentrations of MIF were elevated in overt hypothyroid
patients in comparison with euthyroid and subclinical
hypothyroid patients and controls. We suggest that MIF
may trigger the destruction of thyroid tissue at the later
stage of the thyroiditis. Thyroid destruction in HT is
mostly a consequence of the apoptotic processes com-
bined with CD8+ cell mediated cytotoxicity, changes in
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cytokines such as IFN-ɤ, TNF-α, and IL-1 can influence
immune-mediated apoptosis [22]. MIF may also have a re-
lationship with these cytokines. Further investigations that
evaluate the in-vivo role of MIF and the relation with
other cytokines in HT may increase our knowledge.
The reason why we divided HT patients into euthyr-
oid, subclinical and overt hypothyroidism subgroups was
to analyze the different phases related to disease activity.
In euthyroid and subclinical hypothyroid patients, serum
levels of MIF were not different from the control group.
However overt hypothyroid patients had significantly
higher MIF levels than the euthyroid group. These find-
ings suggest that MIF does not play a role in the initi-
ation phase of HT, however it may play in the later stage
of the disease.
To the best of our knowledge, this is the first report
on the detection of levels of MIF in the peripheral blood
of patients with HT and may be a pilot study to explore
the role of MIF in the pathogenesis of HT.
Monoclonal antibodies targeting TNF- α in rheumatoid
arthritis [23] suggests that similar approaches using cyto-
kine or cytokine receptor antagonists, or using suppressive
cytokines may be successful in the treatment of HT. A re-
cent study using MIF blocking antibodies has found that
therapeutic blockade of MIF reduces the severity and pro-
gression of autoimmune diabetes mellitus [24]. Therefore,
using a MIF antagonist may also be a novel therapeutic
target to prevent the progression of HT.
There are several limitations for the present study. Firstly,
this study involves small number of overt hypothyroid pa-
tients. Moreover, immunohistochemical staining of MIF
in thyroid tissue and correlation with serum MIF levels
may give a better explanation for the role of MIF in the
pathogenesis of HT.
In conclusion, we have shown that MIF increases in
overt hypothyroidism due to the Hashimoto’s thyroiditis.
Further investigations are needed to explore the role of
MIF in pathogenesis of Hashimoto’s thyroiditis.Competing interests
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